Skip to main content

Table 1 Baseline characteristics of the participants at step 1 randomisation

From: Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

  Titrate sertraline up to 50 mg/day by week 3 (n = 970) Titrate sertraline up to 100 mg/day by week 3 (n = 1041)
Demographic characteristics
 Age, year mean (SD) 43.3 (12.2) 41.8 (12.3)
 Female sex, n (%) 572 (59.0) 506 (48.6)
 Education year, mean (SD) 13.8 (2.2) 14.1 (2.5)
 Job status, n (%)
  Employed full-time 398 (41.1) 374 (36.0)
  Employed part-time 103 (10.6) 76 (7.3)
  On medical leave 206 (21.3) 328 (31.6)
  Housewife 114 (11.8) 116 (11.9)
  Student 5 (0.5) 14 (1.4)
  Retired 18 (1.9) 5 (0.5)
  Not employed 124 (12.8) 125 (12.0)
  Missing 2 3
 Marital status, n (%)
  Single, never married 262 (27.1) 355 (34.1)
  Single, divorced or separated 148 (15.3) 124 (11.9)
  Single, widowed 29 (3.0) 25 (2.4)
  Married 528 (54.6) 537 (51.6)
  Missing 3 0
Clinical characteristics
 Age of onset at first episode, years, mean (SD) 38.6 (13.3) 37.1 (13.5)
 Number of previous depressive episodes, mean (SD) 2.3 (4.2) 2.2 (3.1)
 Length of current episode, months, mean (SD) 6.6 (17.2) 5.3 (10.0)
 Inpatient status at time of entry, n (%) 2 (0.2) 3 (0.3)
 PHQ-9 at week 0 18.1 (4.1) 18.8 (3.7)
 PHQ-9 at week 1 14.7 (5.5) 15.9 (4.9)
 BDI-II at week 1 26.2 (10.9) 28.7 (10.6)
  1. BDI-II Beck Depression Inventory 2nd edition, PHQ-9 Patient Health Questionnaire-9